5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety

The study sampled members of an existing US-based group that has facilitated 5-MeO-DMT sessions since 2007. The group's administrator distributed recruitment notices via the group's email newsletter over a four-month period (April–August 2017) inviting members who had attended at least one 5-MeO-DMT group session between 2007 and 2017 to complete an anonymous web survey. Eligibility for the survey included being at least 18 years old, able to read English, and having used 5-MeO-DMT at least once. Participation was anonymous and the research protocol was approved by Bowling Green State University's institutional review board. As an incentive, the researchers donated $2 per respondent (up to $250) to MAPS; MAPS was not otherwise involved in the study. The naturalistic group setting is described in detail. The group used laboratory-tested synthetic 5-MeO-DMT (reported purity 98–100%) and conducted sessions with 5–12 people, typically lasting about 6–7 hours. New members underwent a verbal health screen and a 2-hour orientation. Sessions included environmental preparation, individual check-ins with intention-setting, administration of inhaled 5-MeO-DMT via a custom argon-gas piston vaporiser, and a closing circle with opportunities for integration. Dosing was adjusted by experience/sensitivity: lower (5–7 mg) for limited prior psychedelic experience, medium (8–12 mg) for moderate experience, and higher (≥13 mg) for regular practitioners. Individual experiences lasted about 35–45 minutes and sessions proceeded sequentially until all attendees had received 5-MeO-DMT. Survey procedures: the online survey collected demographic information, 5-MeO-DMT use characteristics, retrospective self-reports of diagnosed depression and anxiety and whether these conditions changed following 5-MeO-DMT use, ratings of acute subjective effects (mystical and challenging) using established subscales, and ratings of personal meaning, spiritual significance, and perceived effects on wellbeing/life satisfaction. No identifying information was collected. The Methods text in the extracted material does not provide all survey item wordings or psychometric details for each measure beyond the mention of standard questionnaires for mystical and challenging experiences.

The authors report that they began with descriptive frequency counts of demographics, 5-MeO-DMT use characteristics, acute subjective effects, beliefs about the experience, and rates of depression and anxiety. The analytic strategy then divided respondents into subsamples who reported a diagnosis of depression or anxiety, and within each diagnostic group compared respondents who reported their condition was "Better" after 5-MeO-DMT use with those reporting "No Change" or "Worse." Group comparisons used chi-square tests and two-sided t-tests for all study variables (demographics, mean ratings of mystical and challenging experiences, beliefs about 5-MeO-DMT, mean dose used, and number of lifetime uses). The researchers used a standard significance threshold of alpha = .05 for hypothesis tests and calculated Cohen's d to estimate effect sizes; analyses were conducted in SPSS v.24. The Results section of the extracted text describes these analytic steps but does not present detailed numerical outcome tables. However, elsewhere in the extracted document the authors report that among respondents who reported a prior diagnosis of depression or anxiety, approximately 80% reported improvement in those conditions following 5-MeO-DMT use (with smaller proportions reporting no change or worsening). Improvement in depression and anxiety was reported to be associated with greater intensity of acute mystical experiences and with higher ratings of the personal meaning and spiritual significance of the session. The authors also report no association between improvements and the intensity of acute challenging experiences, and that improvement was positively associated with younger age. The extracted text does not present the full set of numerical results, confidence intervals, or p-values for these comparisons in the Results section itself.

The authors interpret their findings as suggesting an association between 5-MeO-DMT administered in a structured naturalistic group setting and self-reported improvements in depression and anxiety. They highlight that roughly four in five respondents with a history of depression or anxiety reported improvements after 5-MeO-DMT, and that these improvements were linked to more intense acute mystical-type effects and to higher ratings of personal meaning and spiritual significance attributed to the session. The authors situate these observations alongside laboratory findings with psilocybin showing psychotherapeutic effects when administered with supportive preparation and integration, and they emphasise the potential role of acute mystical experiences as one mechanism by which psychedelic substances may exert therapeutic effects. The authors note that intensity of acute challenging physical or psychological effects was not associated with self-reported clinical improvement. They suggest this may reflect generally low reported intensity of challenging experiences in this sample, and they echo prior literature indicating that challenging experiences, when embedded within structured preparation and integration, can be neutral or positively associated with personally meaningful outcomes. The authors also report an association between younger age and greater likelihood of improvement, proposing that chronicity of illness in older individuals may attenuate apparent benefit, but they state this hypothesis requires prospective testing. The authors acknowledge multiple limitations. The sample was restricted largely to English-speaking, white, heterosexual, college-educated people who participate in a specific 5-MeO-DMT group in the western US, limiting generalisability. The study was cross-sectional and relied on retrospective online self-report rather than prospective or clinician-administered diagnostic instruments, so temporal and causal inferences cannot be made and recall bias may affect responses. The study did not assess current prescription medication use, and many participants reported recent alcohol or cannabis use and some lifetime use of other psychedelics, limiting the ability to attribute effects solely to 5-MeO-DMT. Volunteer bias and favourable views of 5-MeO-DMT among respondents may have skewed reports toward positive outcomes. The authors also note limited statistical power prevented examination of respondents with comorbid depression and anxiety separately. Finally, because these sessions occur within a social community with preparatory and integrative practices, the researchers could not disentangle the effects of social support and community from pharmacological effects of 5-MeO-DMT. Given these limitations, the authors recommend that prospective, controlled laboratory studies are needed to evaluate the safety and therapeutic potential of 5-MeO-DMT. They indicate that structured preparation, administration, and integration—elements present in both their described naturalistic setting and clinical psychedelic research—may be important factors to retain in experimental designs.

The authors conclude that use of 5-MeO-DMT in a structured, naturalistic group setting was associated with spontaneous and unintended improvements in self-reported depression and anxiety among their sample, and that these improvements were related to more intense acute mystical experiences and to higher ratings of personal meaning, spiritual significance, and perceived contributions to wellbeing and life satisfaction. They recommend future prospective experimental studies to assess safety and to examine the therapeutic potential of 5-MeO-DMT under controlled conditions.